Axel Hauschild, MD, PhD, discusses the role of adjuvant and neoadjuvant therapy in melanoma, highlighting the utility of perioperative approaches.
Axel Hauschild, MD
Advertisement
Articles by Axel Hauschild, MD
Axel Hauschild, MD, PhD, discusses research with adjuvant immunotherapy in CSCC and immunotherapy indications in basal cell carcinoma.
Dr. Axel Hauschild, from University Hospital, Schleswig-Holstein, Germany, Discusses the BREAK-3 Trial That Investigated the BRAF Inhibitor Dabrafenib.
Advertisement
Latest Updated Articles
Dr. Hauschild Discusses the Dabrafenib BREAK-3 TrialPublished: June 26th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5